TY - JOUR
AU - Nadesalingam, Angalee
AU - Cantoni, Diego
AU - Aguinam, Ernest T.
AU - Chan, Andrew C.Y.
AU - Paloniemi, Minna
AU - Ohlendorf, Luis
AU - George, Charlotte
AU - Carnell, George W.
AU - Lyall, Jonathan
AU - Ferrari, Matteo
AU - Temperton, Nigel
AU - Wagner, Ralf
AU - Castillo-Olivares, Javier
AU - Baxendale, Helen
AU - Heeney, Jonathan L.
PY - 2022
DA - November
TI - Vaccination and protective immunity to SARS-CoV-2 omicron variants in people with immunodeficiencies
JO - The Lancet Microbe
EP - E59
VL - 4
IS - 2
DO - http://dx.doi.org/10.1016/s2666-5247(22)00297-x
AB - Despite the success of COVID-19 vaccination programmes in reducing morbidity and mortality, a substantial number of individuals in the general population respond poorly to SARS-CoV-2 vaccination. Furthermore, only about 20% of individuals throughout low-income countries have received their first dose of the SARS-CoV-2 vaccine. Neutralising antibodies are a key correlate to protection from COVID-19, with booster vaccines offered to increase protection from new variants. However, poor responsiveness to immunisation increases the risk of infection and disease. The CDC6 reported that patients with compromised immune systems accounted for about 12% of adult COVID-19 hospital admissions and had higher rates of intensive care admissions and in-hospital deaths compared with non-immunocompromised inpatients, in both vaccinated and unvaccinated populations. Although a heterogeneous group, the majority of patients with immunodeficiency show variable and weaker antibody-mediated responses post-vaccination to SARS-CoV-2 than individuals without immunodeficiency. In March, 2022, a UK report revealed 45·5% of immunocompromised individuals received a booster vaccination dose. However, without immune monitoring it remains unclear which individuals within this high-risk population have sufficient immunity.
PB - Elsevier
UR - https://eprints.gla.ac.uk/308210/
KW - Coronavirus (COVID-19)
ER